Cmab Biopharma Inc. and Suzhou Kintor Pharmaceuticals Inc., both of Suzhou, China, are collaborating on the development and manufacturing of Kintor's ALK-1 MAb, a monoclonal antibody targeting activin receptor-like kinase-1 that was licensed from New York-based Pfizer Inc.